Disease Landscape and Forecast Insights

Renal Anemia | Access & Reimbursement | US examines the market access factors that influence the success of therapies for the treatment of renal anemia. The series is based on primary research data…

Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) are serious hospital-treated infections associated with high rates of multi-drug resistant (MDR) bacteria, including…

Introduction Rheumatoid arthritis (RA) affects a significant percentage of Argentinian and Mexican populations and often requires the use of premium-priced biologics. Rheumatologists have…

The increasing prevalence and severity of Gram-negative infections (GNIs) caused by extended-spectrum beta-lactamase (ESBL)-producing pathogens have emerged as a global public health concern…

Sjögren’s syndrome (SS) is an autoimmune disease characterized by dry eyes, dry mouth, and often also systemic manifestations such as fatigue and joint pain. While some SS cases are secondary,…

For migraine patients who suffer from 15 or more migraine days per month (chronic migraine) and/or those patients who suffer from long-lasting migraine attacks or do not experience sufficient…

LaunchTrends: Ibrance (Wave 3) is the third in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the newly launched breast cancer…

Anti-vascular endothelial growth factor (VEGF) therapy is the standard of care for treating wet age-related macular degeneration (AMD), with several commercially available options. Use of off-label…

Although several effective anti-inflammatory agents and bronchodilators are currently available for controlling disease in mild asthmatics, unmet needs exist in treating moderate to severe disease…

Although several effective anti-inflammatory agents and bronchodilators are currently available for controlling disease in mild asthmatics, unmet needs exist in treating moderate to severe disease…

The therapeutic landscape for recurrent or metastatic SCCHN has benefited from the introduction of only one novel treatment in the past several years, Erbitux in 2011. Although Erbitux has improved…

Introduction:The prevalence of psoriatic arthritis (PsA) and ankylosing spondylitis (AS) in Brazil and Mexico is estimated at 1.3 million and is expected to keep growing. The entry of biosimilars…